Imiquimod Treatment for Conjunctival Melanoma In Situ or Ocular Surface Squamous Neoplasia

What is the treatment outcome of compounded imiquimod 5% ointment for diffuse conjunctival melanoma in situ (MIS) or ocular surface squamous neoplasia (OSSN)?In this case series review of 5 adults, 3 achieved complete response and 2 achieved partial response after 12 weeks of treatment with compounded imiquimod 5% in ophthalmic petrolatum-based ointment without safety events of concern identified.Although definitive safety and efficacy cannot be determined across only 5 cases, results of this case series suggest that imiquimod 5% ointment may be a safe and effective approach to manage diffuse conjunctival MIS or OSSN.

Corresponding Author: R. Chris Bowen, MD, MS, Feinberg School of Medicine, Northwestern University, 259 E Erie St, Ste 1520, Chicago, IL 60611 (rcbowenmd@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.